[go: up one dir, main page]

WO2017083579A1 - Système et protocole de cicatrisation de plaie assistée par laser - Google Patents

Système et protocole de cicatrisation de plaie assistée par laser Download PDF

Info

Publication number
WO2017083579A1
WO2017083579A1 PCT/US2016/061423 US2016061423W WO2017083579A1 WO 2017083579 A1 WO2017083579 A1 WO 2017083579A1 US 2016061423 W US2016061423 W US 2016061423W WO 2017083579 A1 WO2017083579 A1 WO 2017083579A1
Authority
WO
WIPO (PCT)
Prior art keywords
laser
substrate
instrument
wound
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/061423
Other languages
English (en)
Inventor
Margaret KALMETA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioregentech LLC
Original Assignee
Bioregentech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/937,858 external-priority patent/US11730760B2/en
Application filed by Bioregentech LLC filed Critical Bioregentech LLC
Priority to CA3005045A priority Critical patent/CA3005045C/fr
Priority to CN201680072908.0A priority patent/CN108430577A/zh
Priority to JP2018525412A priority patent/JP2019502425A/ja
Priority to AU2016353150A priority patent/AU2016353150B2/en
Priority claimed from US15/348,793 external-priority patent/US11389663B2/en
Publication of WO2017083579A1 publication Critical patent/WO2017083579A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0468—Specially adapted for promoting wound healing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0644—Handheld applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Definitions

  • the present invention relates generally to a method of treating gum diseases using a diode laser which produces a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm - 700nm).
  • the laser light utilizes green wavelength range (520 - 570 nm) at a laser power 0.001 W to 5W to treat wounds. It is also contemplated that described is a method of treating diseased tissue using a diode laser.
  • the laser light utilizes the IR wavelength range (700nm - 1400nm) at a laser power of .001W to 5W to treat wounds.
  • an LED light utilizes the IR wavelength range to treat wounds.
  • LAPOR Laser Assisted Periodontium and Osseous Regeneration
  • a substrate such as but not limited the LAPOR periodontal solution, the LAPOR periodontal gel and the LAPOR substrate and thus causes an increase in cell attachment of epithelial cells, gingival fibroblasts, PDL fibroblasts and adhesion of osteogenic cells.
  • Enhanced cell migration and proliferation appears to lead to accelerated wound fill rates in vitro using PDL fibroblasts, gingival fibroblasts and osteoblast-like cells.
  • a substrate such as the LAPOR periodontal solution, the LAPOR periodontal gel and the LAPOR substrate, used in the LAPOR protocol stimulates total protein synthesis and the synthesis of specific extracellular matrix molecules.
  • Studies that evaluate the bone remodeling regulation system indicate that proteins influence this regulation system, thus indicating an indirect involvement in the bone remodeling process.
  • LAPOR When used in conjunction with three specially formulated periodontal and wound healing substrates, and LAPOR gel root conditioner, LAPOR has shown to stimulate total tissue and bone synthesis, increase gingival attachment, gingival height, bone density, bone height thereby showing accelerated wound fill rates in vivo.
  • the diode laser used produces a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm - 700nm).
  • a beam of light having a wavelength in the green wavelength range (520 - 570 nm) at a laser power of 0.5 to 1.2W is used in the LAPOR protocol. It has been shown by the LAPOR protocol to biostimulate the healing and regenerative processes of the periodontium, including the biostimulation of new bone and its supporting elements.
  • the diode laser used in the LAPOR protocol biostimulates the healing response of the periodontium nonsurgically, and biostimulates the tissue regeneration of the periodontium, nonsurgically, and prevents long junctional epithelium from migrating downwards into the sulcus (a biomechanical aspect of tissue healing), thereby preserving the tissue height.
  • a diode laser used in the LAPOR protocol helps a substrate such as but not limited to proteins to stimulate total protein synthesis and the synthesis of extracellular matrix molecules, nonsurgically.
  • the LAPOR protocol may use a beam of light having a wavelength in the green wavelength range (520-570 nm), red wavelength range (620-750 nm), or yellow wavelength range (570-590 nm) having an alternative wattage of 0.001 W to 5W, preferably 0.002W to 4W, more preferably 0.003W to 4W, and most preferably 0.005W to 2W.
  • the diode laser used helps the substrates stimulate total tissue and bone synthesis by biostimulating the healing response and bone/tissue regeneration and its supporting elements of the wound.
  • the invention may be used to treat tissue damage and wounds, i.e. Laser Assisted Tissue and Osseous Regeneration (LATOR) using a solution, LATOR gel and LATOR substrate to enhance cell migration and proliferation leading to accelerated wound fill rates.
  • LATOR Laser Assisted Tissue and Osseous Regeneration
  • the protocol is used in conjunction with six specially formulated tissue and wound healing substrates and a gel conditioner to stimulate total tissue and bone synthesis, increase tissue attachment, tissue height, bone density and bone height thereby showing accelerated would till rates like the LAPOR protocol.
  • a method of treating wounds including gum disease and gingival tissues post scaling/root planning, using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400nm - 700nm).
  • a beam of light having a wavelength in the green range (520 - 570 nm) at a laser power of 0.5 to 1.2 watts is used to decontaminate the gum tissue and to biostimulate healing and regenerate the periodontium (including cementum of the root surface), thus preventing long junctional epithelium from migrating downwards into the sulcus and thereby preserving the tissue height.
  • a beam of light having a wavelength in the green wavelength range (520-570 nm), red wavelength range (620-750 nm), or yellow wavelength range (570-590 nm) having an alternative wattage of 0.001 W to 5W may be used to biostimulate healing and regenerate the wound site, its tissue and bone.
  • the wattage is in the range of 0.002W to 4W, more preferred in the range of 0.003 to 3W, and most preferred in the range of 0.005W to 2W.
  • a diode laser also biostimulates the healing and regenerative response induced by a substrate, i.e.
  • the LAPOR periodontal and wound healing solution, the LAPOR periodontal gel and the LAPOR periodontal and wound healing substrates comprising: 1) placing the laser inside the sulcus; 2) penetrating the entire sulcus by moving the laser light intermittently vertically and horizontally throughout the sulcus; and 3) placing the substrate in the sulcus prior to a blood clot forming (which then increases cell attachment, adhesion, migration and proliferation).
  • the LATOR protocol may use a diode laser per the above parameters to treat general wound sites.
  • the laser light utilizes the IR wavelength range (700nm - 1400nm) at a laser power of .001 W to 5W to treat wounds.
  • the LAPOR protocol may use an LED light to biostimulate healing and regenerate periodontium and general wound tissue (LATOR protocol).
  • the LED light is used at 10W or lower on wounds to assist in new cell organization and hence tissue regeneration.
  • an LED light utilizes the IR wavelength range to treat wounds.
  • the laser light utilizes the IR wavelength range (700nm - 1400nm) at a laser power of .001 W to 5W to treat wounds.
  • the LAPOR and LATOR protocols may use a
  • radiofrequency (RF) wave to decontaminate the gum tissue and biostimulate healing and regenerate the periodontium.
  • the RF beam is used at 10W or lower on wounds to assist in new cell organization and hence tissue regeneration.
  • a carrier wave (sine wave) transports a non- sinusoidal waveform to the treatment location.
  • the carrier wave frequency may be in the range of 0.1MHz to 20MHz while the non-sinusoidal waveform may be in the range of 0 to 40 KHz or alternatively 0 - 24 GHz.
  • the carrier wave frequency is in the range of 0.2MHz to 10MHz, preferably 0.3MHz to 5MHz.
  • the 0.001 W to 10 watt range preferably a 0.001 W to 3W range, is utilized in the hertz range of 40 Hz to 24 GHz.
  • the RF wave is a single sine wave.
  • the RF wave is more than one sine wave wherein the more than one demonstrates a harmonics pattern.
  • the LATOR protocol may use an RF wave per the above parameters to treat general wound sites.
  • the non-sinusoidal waveform may be in the range of the above parameters in the absence of a carrier wave.
  • a root/bone/cartilage conditioner comprised of EDTA 15%, calcium gluconate 20%, methylparaben, propylparaben, Ethanolamine as a buffering agent, carboxymethylcellulose, and green food coloring and sterile water.
  • first substrate comprised of: a combination of mono or disodium phosphate and sodium hydroxide in solution with a sodium content of 1 lmg/lOOg; 60% water; 9% Lysine; 9% Proline; 9% all other essential amino acids wherein the amino acids are chosen from the group consisting of Isoleucine, Leucine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Histadine, Asparagine and Selenocysteine; 2% of all other non-essential amino acids wherein the amino acids are chosen from the group consisting of Alanine, Arginine, Aspartate, Cysteine, Glutamate, Glutamine, Glycine, Serine, Tyrosine and Pyrrolsine; 6.9% free bases wherein the free bases are chosen from the group consisting of adenosine, uridine, guanosine, iridin and cytidine; 2% phosphate
  • a second substrate comprised of: tricalcium phosphate wherein the tricalcium phosphate is precipitated with calcium hydroxide/Claw oil; and hydroxyapante crystals.
  • third substrate comprised of: 5.1 % hyaluronic acid; 8% fatty acids wherein the fatty acids are chosen from the group consisting of Linoleic acid (LA), alpha-linolenic acid (ALA), 4.4% sugars wherein the sugars are chosen from the group consisting of mannose, galactose, N-acetylglactosamine, N- acetylglucosamine, N-acerylneurarninic acid, fucose (L configuration minus a carboxyl group at the 6 position), and xylose; 2.2% mixture of glucose and fucose (L configuration minus a carboxyl group at the 6 position); 3% lipids wherein the lipids are chosen from the group consisting of vitamin A, vitamin D2, D3, vitamin E, vitamin K1, K2, vitamin B12 (methylcobalammn, hydroxocobalamin), cholesterol, and diaglycerol; 2.7% vitamins wherein the vitamins are chosen from the group consisting of the group consisting of vitamin A, vitamin
  • a fourth substrate comprised of carbomer, potassium chloride, chloride, sodium, potassium, manganese, calcium triphosphate, sulfate, carbonate, snail serum, snail secretion filtrate, HA, Au, Ag, Cu, Fe, Pt, collagen, glyceine HC1 and fucose.
  • fifth substrate comprised of a tricalcium phosphate and/or collagen limed and/or collagen unlimed.
  • a sixth substrate comprised of tricalcium phosphate and/or collagen limed and/or collagen unlimed and/or HC1 and/or NaCl, and/or metals wherein the metals are chosen from the group consisting of copper, Au, Ag, iron and platinum or any combination thereof.
  • Fig. 1 shows an X-Ray view of a patient's teeth before treatment with a diode laser before a substrate has been applied.
  • Fig. 2-7 show X-Ray views of the lower teeth of Fig. 1 after treatment with a diode laser after treatment with a substrate.
  • Fig. 8 shows an X-Ray view of the upper teeth before treatment with a diode laser after treatment with a substrate.
  • Fig. 9 shows an X-ray view of the upper teeth of Fig. 8 after treatment with a diode laser after treatment with a substrate.
  • Fig. 10 shows a flow diagram of a method of using a diode laser to treat gum disease in accordance with the principles of the invention.
  • Fig. 11 shows bone density measurements for tooth 15 of a patient at 12 loci on the tooth following treatment with a diode laser and a substrate over time.
  • Fig. 12 shows bone density measurements for tooth 28 of a patient at 17 loci on the tooth following treatment with a diode laser and a substrate over time.
  • Fig. 13 shows bone density measurements for tooth 2, tooth 3 and tooth 15 of a patient at 3 loci per tooth following treatment with a diode laser and a substrate over time.
  • Fig. 14a and 14b show X-rays of tooth 15 of a patient from which measurements shown in Fig. 11 were collected, (a) shows tooth 15 before treatment, (b) shows tooth 15 at the October 2011 measurement following three treatments.
  • Fig. 15a and 15b show X-rays of tooth 28 of a patient from which measurements shown in Fig. 12 were collected, (a) shows tooth 28 before treatment, (b) shows tooth 28 at the January 2011 measurement following four treatments.
  • Fig. 16a and 16b show a panoramic X-ray of tooth 2, tooth 3 and tooth 15 of a patient from which measurements shown in Fig. 13 were collected, (a) shows the teeth before treatment (b) shows the teeth at the July 2011 measurement.
  • Fig. 17a-17f show various views of a first embodiment of a diode laser of the present invention, (a) shows a right side view, (b) shows a back side view, (c) shows a left side view, (d) shows a front side view, (e) shows a top view, (f) shows a bottom view.
  • Fig. 18a-18c show an exploded view of the diode laser of Fig. 17.
  • (a) shows an exploded view
  • (b) shows an assembled view
  • (c) shows a close-up of the laser housing.
  • Fig. 19a-19g shows various views of a second embodiment of a diode laser of the present invention, (a) shows a top perspective view, (b) shows a back view, (c) shows a left side view. (d) shows a top view, (e) shows a front perspective view, (f) shows a right side view, (g) shows a bottom view.
  • Fig. 20a and 20b an exploded view of the diode laser of Fig. 19.
  • (a) shows an exploded view
  • (b) shows a close- ⁇ of the laser housing.
  • Fig. 21a-21c show various view of a third embodiment of the diode laser of the present invention, (a) shows a side perspective view, (b) shows an exploded view, (c) shows a close-up view of the laser housing.
  • Fig. 22a-22c shows a fiber optic laser of the present invention, (a) shows an assembled view, (b) shows an exploded view, (c) shows a fully assembled laser.
  • Fig.23 shows a flow chart of the protocol for using a laser of the present invention.
  • Fig.24 shows chin profile measurements before and after treatment.
  • Fig. 25 shows toe crease length measurements before and after treatment.
  • Fig. 26a-26c show gingival wound healing and tissue regeneration measurements before and after treatment, (a) shows wounds before treatment, (b) shows tissue regeneration after treatment, (c) shows tissue height measurements before and after treatment.
  • Fig. 27 shows hand crease length measurements before and after treatment.
  • Fig. 28 shows wound new skin growth measurements before and after treatment.
  • Fig. 29 shows (anal) scar width reduction measurements before and after treatment
  • Fig. 30 shows (anal) scar length reduction measurements before and after treatment.
  • Fig. 31 shows swallowing strength measurements before and after treatment.
  • Fig.32 shows breast firmness measurements before and after treatment
  • Fig. 33a-33e show various views of an RF hand piece of the present invention, (a) shows a top view, (b) shows a side view, (c) shows a perspective view of the RF tips, (d) shows an exploded side perspective view, (e) shows an alternative side perspective view.
  • Fig.34a-34f show various views of a fourth alternative diode laser of the present invention, (a) shows a right side view, (b) shows a front view, (c) shows a left side view, (d) shows a left side perspective view, (e) shows a top view, (f) shows a right side perspective view.
  • Fig. 35a-35f show various views of a laser power source for the fiber optic hand piece and interchangeable tips.
  • Fig. 36a-36f shows various views of a portable RF transmitter of the present invention, (a) shows a top view, (b) shows a front view, (c) shows a bottom view, (d) shows a left side view, (e) shows a left front perspective view, (f) shows a right front perspective view.
  • Fig. 37a-37b show alternative fiber optic lasers of the present invention, (a) shows a flat tip. (b) shows a glass dispersion tip.
  • Fig. 38 shows epithelial wound regeneration before and after treatment.
  • Fig. 39 shows cancaeal tendon wound regeneration before and after treatment.
  • Fig.40 shows ankle epithelial wound regeneration before and after treatment.
  • Fig.41 shows ankle wound size reduction before and after treatment
  • Fig.42 shows oral cavity wound regeneration before and after treatment
  • Fig.43 a-b shows (a) vein wound regeneration before and after treatment and (b) a flashlight style infrared laser.
  • gingivitis means periodontal disease which can lead to tooth loss and/or other health problems.
  • periodontal disease include gingivitis, aggressive periodontitis, chronic periodontitis, periodontitis as a manifestation of systemic diseases, and necrotizing periodontal disease.
  • tissue disease means tissue and/or epithelial loss due to injury and/or wounds which can lead to other health problems such as amputation of limbs.
  • the term "patient” means any individual suffering from a disease of the gums and in need of treatment for said gum disease.
  • locus means an exact point of measurement within the sulcus or the immediate surrounding area.
  • substrate mixture means the mixture of the first substrate and/or the second substrate and/or the third substrate and/or the fourth substrate and/or the fifth substrate and/or sixth substrate disclosed herein for treatment of gum disease and/or tissue disease and/or wounds.
  • bone regeneration means increasing the density of calcium at specific loci in or around the sulcus.
  • calcium density means the measurement of calcium mass around a given loci.
  • wound means any area that has lost any original tissue or bone or any other structure not named that lost a healthy non- wounded, undamaged and imaged form.
  • the LAPOR protocol can be used in the treatment of gum disease and wounds by combining the most effective methods of treatment with the use of a special laser. Approximately 66% of the United States population has some form of gum disease. But many avoid seeking treatment because of the discomfort that often results from gum surgery. LAPOR provides a new choice.
  • the LAPOR protocol is a treatment that is more effective as traditional periodontal surgery, and it is much more beneficial to the patient both in the short term and in the long run.
  • the LATOR protocol can similarly be used for treatment of tissue disease and wounds.
  • the LAPOR protocol takes only about an hour and only two short follow-up visits. Patients enjoy no downtime with recovery taking only 24 hours. This makes immediate return to work both possible and comfortable.
  • gum recession is zero when compared to that which most often follows normal periodontal surgery. This, combined with new cementum formation on the roots, bone formation in previous defects, periodontal ligament formation and no tooth loss.
  • wound fibrosis is zero compared to that which most often follows normal treatment, new tissue formation occurs multi directionally and the wound closes without grafting.
  • the LAPOR protocols of the present invention can be used to heal wound sites by combining or using separately the most effective methods of treatment with the laser, LED, radiofrequency energy and substrates. Following performance of treatment protocols, no receding of tissue from the wound site was observed.
  • the RF energy waves may be up to 10W.
  • the carrier wave frequency may be in the range of 0.1 MHz to
  • the non-sinusoidal waveform may be in the range of 0 to 40 KHz or from 0 to 24GHz.
  • the carrier wave frequency is in the range of 0.2MHz to 10MHz, preferably 0.3MHz to 5MHz.
  • a 0.001 W to 10W range RF energy preferably a 0.001 W to 3W range, is utilized in the hertz range of 40 Hz to 24 GHz.
  • the RF wave is more than one sine wave wherein the more than one demonstrates a harmonics pattern.
  • the special type of laser used in the LAPOR protocol and the LATOR protocol is the diode, a semiconductor coherent light beam used on s.
  • the laser light used has a wavelength in the visible portion of the electromagnetic spectrum, between 400nm - 700nm wavelength.
  • the green range (520 - 570 nm) of the visible spectrum is utilized at a laser power of 0.5 to 1.2 watts, which disinfects the site, leaving the gum tissue bacteria free, and biostimulates healing; in conjunction with treatment with a substrate, the laser biostimulates regeneration of the periodontium.
  • Traditional periodontal therapy removes tissue height of a tooth to reduce the pocket depths.
  • the LAPOR protocol is a regenerative procedure. The patient does not lose tissue volume.
  • the laser biostimulates regeneration of tissue where traditional therapy removes tissue height to reduce the disease.
  • the laser light utilizes the IR wavelength range (700nm - 1400nm) at a laser power of .001W to 5W to treat wounds.
  • LED light is used at 10W or lower.
  • the use of the diode laser in conjunction with routine scaling and root planning is more effective than scaling and root planning alone. It enhances the speed and extent of the patients gingival healing and postoperative comfort. This is accomplished through laser bacterial reduction and biostimulation with a laser light having a wavelength in the visible portion of the electromagnetic spectrum, between 400nm - 700nm wavelength.
  • the green range (520 - 570 nm) of the visible spectrum is utilized at a laser power of 0.5 to 1.2 watts.
  • the laser power wattage may be in the range of 0.001W to 5W, preferably 0.002W to 4W, more preferably 0.003W to 3W, and most preferably 0.005W to 2 W.
  • the green range (520 -570 nm) ofthe visible spectrum is utilized at a laser power of 0.5 to 1.2 watts to treat gum disease.
  • a perio probe determines the degree of excessive pocket depth and thus helps the dentist better identify diseased tissue and areas of bacterial infection.
  • the dentist removes calculus from the root surface using an ultrasonic scaler and hand instruments, block 14. This action by the dentist helps stimulate a healing response in the sulcus by opening the capillaries upon scaling.
  • the laser tip is placed inside the sulcus and a continuous light beam with intermittent stops for tissue temperature control is allowed to penetrate the entire sulcus by moving the tip vertically and horizontally throughout the sulcus.
  • the laser tip is cut at a 45 degree angle during the first pass.
  • the laser is cut at the opposite 45 degree angle during the second pass. This allows for the laser beam to penetrate the existing periodontium to decontaminate the tissue, as the heat of the targeted laser light kills the bacteria. This also allows for biostimulation of the sulcular contents.
  • the dentist scales the sulcular area and root surfaces once again to induce a healing response through renewed blood flow.
  • At least one substrate such as but not limited to matrix proteins, is then placed in the sulcus of the tooth prior to the blood clot forming and at block 24, a blood clot is carefully allowed to form by gently helping patient keep their mouth open for 5 minutes, to keep the substrate intact.
  • the laser light utilizes the IR wavelength range (700nm 1400nm) at a laser power of .001 W to 5W to treat wounds.
  • the laser tip is a specially designed tip that disperses light energy throughout the wounded sulcus which allows the laser beam to penetrate the existing tissues to decontaminate the tissue, as the heat of the targeted laser light kills the bacteria and as a result block 20 may be eliminated going directly to block 22
  • Fig. 17a- 17f shown are various angles of the first embodiment of a device 100 for use in conjunction with the substrates and methods of the present invention.
  • Fig. 18a and 18b show perspective views of the device 100 in the first embodiment. Specifically, Fig.
  • FIG 18a illustrates an exploded view of the device 100 comprised of cord 101 integrally connected to handle 109, handle 109 further connected to heat sink 102.
  • Housing 103 securely connects to heat sink 102 thereby creating a cavity between the housing 103 and heat sink 102.
  • Laser 104 is positioned within the cavity between housing 103 and heat sink 102.
  • Male connectors 105 connect RF source 108 to housing 103 wherein threaded inserts 106 cover the connection therebetween.
  • Cap 107 is positioned over housing 103 and secures to handle 109.
  • FIG 18c shows a detailed view of heat sink 102, laser 104, housing 103 and male connectors 105 in relation to each other.
  • the device 100 may have a plurality of RF sources 108 wherein a plurality is defined as at least two tips (i.e. dipole).
  • Housing 103 is capable of movement such that RF source 108 may be adjusted 45° up or down relative to the x- axis for ease of use depending upon the location of the wound receiving treatment.
  • the laser energy may have wavelength in the green wavelength range (520-570 nm), red wavelength range (620-750 nm), or yellow wavelength range (570-590 nm) having a wattage of 0.001 W to 5W.
  • laser energy has a wattage of .001 W to 5W.
  • the wattage is in the range of 0.001 W to 4W, more preferred in the range of 0.003 to 3 W, and most preferred in the range of 0.005W to 2W.
  • the RF energy may have a power of 10 watts or lower.
  • the carrier wave frequency may be in the range of 0. lMHz to 20MHz while the non-sinusoidal waveform may be in the range of 0 to 40 KHz or from 0 to 24GHz.
  • the carrier wave frequency is in the range of 0.2MHz to 10MHz, preferably 0.3MHz to 5MHz.
  • a 0.001W to 10W range RF energy preferably a 0.001 W to 3W range, is utilized in the hertz range of 40 Hz to 24 GHz.
  • the RF wave is more than one sine wave wherein the more than one demonstrates a harmonics pattern.
  • the non-sinusoidal waveform may be in the range of the above parameters in the absence of a carrier wave. Referring to Fig. 19a-19g, shown are various angles of a second embodiment of a device 200 for use in conjunction with the substrates and methods of the present invention. Fig.
  • FIG. 20a shows a perspective view of the device 200 of the second embodiment
  • Fig. 20a illustrates an exploded view of the device 200 comprised of wire grommet 201 integrally connected to handle 209, handle 209 further comprised of heat sink 202.
  • Housing 203 securely connects to heat sink 202 thereby creating a cavity between the housing 203 and heat sink 202.
  • Laser 204 is positioned within the cavity between housing 203 and heat sink 202.
  • Male connectors 205 connect RF source 208 to housing 203 wherein threaded inserts 206 cover the connection there between.
  • Fig. 20b shows a detailed view of laser 204 and housing 203 in relation to each other.
  • Fig. 21a-21c shown is a third embodiment of a device 300 for use in conjunction with the substrates and methods of the present invention.
  • Fig.21a shows a perspective view of the device 300 of the second embodiment.
  • Fig. 21b illustrates an exploded view of the device 300 comprised of wire grommet 301 integrally connected to housing 303, housing 303 further comprised of heat sink 302. Housing 303 securely connects to heat sink 302 thereby creating a cavity between the housing 303 and heat sink 302.
  • Laser 304 is positioned within the cavity between housing 303 and heat sink 302.
  • Male connectors 305 connect RF source 308 to housing 303 wherein threaded inserts 306 cover the connection there between.
  • Fig. 21c shows a detailed view of laser 304 and housing 303 in relation to each other.
  • the device may have five or six tips.
  • Fiber optic device 400 for use in conjunction with the substrates and methods of the present invention.
  • Fiber optic device 400 is comprised of hand grip assembly 401 disposed between a first end and a second end.
  • the first end is further comprised of nose insert 402 positioned between hand grip assembly 401 and removable nose assembly 404.
  • Bent fiber tube 405 extends from removable nose assembly 405.
  • the second end is further comprised of base insert 406 positioned between hand grip assembly 401 and rubber boot 407. Extending from rubber boot 407 is sheathed fiber 408 having a SMA connector 409 at the end opposite rubber boot 407.
  • Fig. 22c shows a fully assembled fiber optic device 400 further comprising a body for housing the laser source.
  • the conditioner is applied to the root or bone surface.
  • the root conditioner comprises the following at Table 1 :
  • the conditioner is optionally rinsed out prior to application of additional substrates or laser light.
  • the conditioner is left on the root or bone surface with the laser light being applied prior to application of any substrate.
  • the conditioner is left in with only one substrate applied prior to application of the laser light.
  • the conditioner is left in the sulcus and substrate is added prior to any application of laser light
  • the placement of the substrate into the sulcus containing luminesced blood enables the luminesced blood to coagulate upon the substrate.
  • liquid substrate or substrate 1 is comprised of the following, per 1L of solution, at Table 2:
  • the total sterile water component is adjusted 20% up or down, depending on the desired viscosity to be achieved.
  • liquid substrate or substrate 1 is comprised of the following, at Table 3:
  • an additional substrate may be applied, the additional substrate, substrate 2, comprised of: tricalcium phosphate wherein the tricalcium phosphate is precipitated with calcium hydroxide/Claw oil; and hydroxyapatite crystals.
  • an additional substrate may be applied, the additional substrate, substrate 3, is comprised of the following at Table 4:
  • the total sterile water component is adjusted 20% up or down, depending on the desired viscosity to be achieved.
  • an additional substrate may be applied, the additional substrate, substrate 4, is comprised of the following at Table 5:
  • the total sterile water component is adjusted 20% up or down, depending on the desired viscosity to be achieved.
  • Substrates 1, 2 and 3 may have different modalities of delivery, for example, drops, sprays, injections or intravenous having the same ingredients, as well as sublingual, anal, foam and ointment formulations or drinkable liquids.
  • an additional substrate may be applied, the additional substrate 5 is comprised of the following:
  • collagen supplemented with porous tri calcium phosphate crystals with one size or variety of sizes: 4-50 ⁇ m, 50-150 urn, 100-300 ⁇ m, 500-1000 ⁇ m, l-3mm and 3-6 mm.
  • the tricalcium phosphate crystals may be dense or porous.
  • substrate 5 may be used in the absence of other substrates.
  • an additional substrate may be applied, the additional substrate 6 is comprised of the following:
  • Collagen supplemented with porous tricalcium phosphate crystals with one size or variety of sizes: 4-50 ⁇ m, 50-150 um, 100-300 ⁇ m, 500-1000 um, l-3mm and 3-6mm.
  • the tricalcium phosphate crystals may be dense or porous.
  • substrate 6 may be used in the absence of other substrates.
  • An additional substrate may be applied, the additional substrate comprised of the following: a mixture of tricalcium phosphate and hydroxyapatite crystals.
  • the tricalcium phosphate is precipitated with CaOH/devil's claw oil, in a preferred embodiment.
  • the additional substrate includes 50% tricalcium phosphate/devil's claw oil precipitated with 50% porous hydroxyapatite crystals.
  • the tricalcium phosphate crystals used are granules in the following sizes: 4-50 ⁇ m, 50-150 ⁇ m, 100-300 ⁇ m, 500-1000 ⁇ m, 1-3 mm and 3-6 mm.
  • the tricalcium phosphate crystals may be dense or porous.
  • the additional substrate may be comprised of hydroxyapatite crystals of granules containing the following sizes: 10-50 ⁇ m, 50-150 ⁇ m, 100-300 um, 500-1000 ⁇ m, l-3mm and 3- 6 mm.
  • the hydroxyapatite crystals may be dense or porous.
  • the conditioner is applied and subsequently rinsed out
  • the conditioner is left in the sulcus, as the conditioner allowed the micropores within the tooth structures to remain open.
  • the conditioner After the conditioner is applied, the sulcus is biostimulated with a laser light. After this occurs, the liquid substrate is applied. Optionally, the additional substrate is applied. For cavities other than oral cavities, a diluted substrate assists treatment when ingested or taken via IV is beneficial although not required.
  • an optional spray substrate, spray 1 may be applied, the spray comprised of the following: Au, Ag, Cu, Fe, Pt, and sterile water.
  • an optional spray substrate, spray 2 may be applied, the spray comprised of the following: CI, Na, K, Mg, Phosphate, Sulfate, bicarbonate and sterile water.
  • the fiber optic device of the present invention is the sole device placed inside the sulcus for treatment.
  • the sulcus may also be treated with laser, RF or laser with RF.
  • the remaining disclosed embodiments of the device may be used in wound treatment in conjunction with the substrates depending on the wound site and severity of the wound.
  • Substrates disclosed herein may be a form including, but not limited to, liquid, tablet, enema, gel, injection or foam.
  • step 4 circumferentially vertically and horizontally around tooth until the entire sulcular wound has been saturated by laser energy
  • step 2-6 wait a week in between step 2-6 and gradually cover wound bed.
  • Treatment of the oral cavity, head/neck, tongue, anal, vaginal region and the deeper areas reached while treating these may be performed with the RF with substrate (applied substrate or drank with water), RF without substrate, RF plus laser with substrate (applied substrate or drank with water), RF plus laser without substrate and laser with substrate (applied substrate or drank with water), laser without substrate.
  • the treatment described may be utilized throughout the gastrointestinal tract, head/neck and anus.
  • the laser, RF or LED treatment applied to the oral cavity and surrounding structures, anal cavity and its surrounding structures, head and neck region and its surrounding structures has benefits in deeper areas of the structures. Those deeper areas of the corresponding structures are thus part of the treatment site.
  • Surrounding structures include, but are not limited to, all bone, cartilage, muscles, tendons, nerves, blood vessels, epithelium and fascia.
  • Surrounding structures include, but are not limited to, all bone, cartilage, muscles, tendons, nerves, blood vessels, and epithelium.
  • Head and neck includes, but is not limited to, all structures of the head and neck including esophagus and its surrounding structures, mouth including all interior mouth structures such as tongue (entire area of tongue including but not limited to anterior, posterior, dorsal, ventral, and sublingual), floor of mouth including but not limited to arterial and nerve beds, linea alba, buccal mucosa, buccal flanges, lingual flanges, nose, interior of nose (including but not limited to the epithelial lining), all muscles and other structures of the tongue and surrounding the tongue, all muscles of the eye and surrounding the eye, all arterial, venous and nerve beds of the eye and surrounding the eye. AH muscles, nerves, veins, all glands and tissue of the head and neck and any other structure of the head and neck.
  • Surrounding structures include, but are not limited to, all bone, cartilage, muscles, tendons, blood vessels, and epithelium.
  • Surrounding structures include, but are not limited to, all bone, cartilage, muscles, tendons, nerves, blood vessels, and epithelium and any other structures of the anal cavity.
  • Related structures include, but are not limited to, all bone, cartilage, muscles, tendons, nerves, blood vessels, lymph nodes and epithelium.
  • Surrounding structures include, but are not limited to, all bone, cartilage, muscles, tendons, nerves, blood vessels, and epithelium.
  • Surrounding structures include, but are not limited to, all bone, cartilage, muscles, tendons, blood vessels, and epithelium.
  • Surrounding structures include, but are not limited to, all bone, cartilage, muscles, tendons, blood vessels, and epithelium.
  • RF and/or laser and/or LED assisted oral cavity wound repair 1. Drink 4 oz. diluted Substrate 1, and/or 2, and/or 3, and/or 4, and/or 5 and/or 6;
  • Surrounding structures include, but are not limited to, all bone, cartilage, muscles, tendons, nerves, blood vessels, and epithelium.
  • wound treatment may be utilized for additional conditions including, but not limited to, vaginal wound repair, breast wound repair/regeneration/generation, anal wound repair, age spot repair, pore repair, skin and tissue repair and general body wound repair.
  • Fig. 33a-33e shown is a fourth embodiment of a device 500 for use in conjunction with the substrates and methods of the present invention.
  • Fig. 33 a shows a top view of the device 500 of the fourth embodiment.
  • Fig. 33b shows a side view and
  • Fig. 33c shows a close-up of the tip of device 500.
  • Fig. 33d illustrates an exploded view of the device 500 comprised of housing 503, tips 505 and energy source 507.
  • Energy source 507 provides RF energy to housing 503 when connected.
  • Fig. 33e shows a side perspective view of the assembled device 500.
  • the device 500 may be used in the absence of substrates.
  • Fig. 34a-34f shown is a fifth embodiment of a device 600 for use in conjunction with the substrates and methods of the present invention.
  • Fig. 34d and 34f show side perspective views of device 600.
  • Fig. 34a shows a side view of device 600 wherein device 600 has a hemispheric shape and is further comprised of a flat surface opposite the hemispheric surface.
  • the flat surface is further comprised of a plurality of mini lasers 605 for delivery of diode laser energy for treatment of an acute wound.
  • the mini lasers 605 are self-contained within device 600.
  • the laser power used for treatment may be approximately 6-24 mW.
  • Fig. 35a-35f shown is power device 700 for a fiber optic had piece for use in conjunction with the substrates and methods of the present invention.
  • Fig. 35a shows the components of pocket power device 700, the pocket power device 700 further comprised of a base 701 , a battery mount 702, a rechargeable battery 703, a handle for a fiber optic laser 704, and a top 705.
  • Fig. 35b-35f show various views of the pocket power device 700.
  • the handle 704 is a self- contained unit having an attached fiber optic line 706 upon which a fiber optic laser head (not shown) is connected. Further, a diode laser module is housed in pocket power device 700.
  • a portable RF transmitter 800 for use in conjunction with the substrates and methods of the present invention.
  • Fig. 36e and 36f show side perspective views of RF transmitter 800.
  • Fig. 36a shows a top view;
  • Fig. 36b shows front view;
  • Fig. 36c shows a bottom view;
  • Fig. 36d shows a left side view.
  • the RF transmitter 800 may be used in the absence of substrates.
  • FIG. 37a-37b shown are alternative embodiments of interchangeable fiber optic tips for a laser for use in conjunction with the substrates and methods of the present invention.
  • Fig. 37a shows an interchangeable fiber optic tip for a laser having a nose piece 900 and a flat tip 901.
  • Fig. 37b shows an interchangeable fiber optic tip for a laser having a nose piece 900 and a glass dispersion tip 902.
  • a patient's pocket depths at tooth 15 were measured at 12 separate loci.
  • the root of the tooth was then scaled and planed to remove calculus build up on the root surface. After scaling and planning, bleeding occurs in the sulcus.
  • the sulcus was allowed to air dry and immediately thereafter the conditioner is applied to the sulcus and left for 30 seconds before being rinsed with saline.
  • the tooth was next scaled and planed again to renew blood flow. With blood pooling in the sulcus, the 45° laser tip was placed into the sulcus.
  • the laser light used has a wavelength in the visible portion of the electromagnetic spectrum, between 400nm - 700nm wavelength. The laser was emitted continuously with only intermittent stops for tissue temperature control.
  • the laser was allowed to penetrate the entire sulcus by moving the tip vertically and horizontally throughout the sulcus for 30 second.
  • the laser tip was cut to 45° in the opposite angle for the second pass into the sulcus and 90° for the third pass to allow the laser bean to penetrate the existing periodontium to decontaminate and biostimulate the sulcular contents.
  • the first substrate and the second substrate were mixed in a glass dish.
  • Some of the patient's blood that has been treated with the laser light in the sulcus was also mixed in the glass dish. This mixture is then placed immediately into the sulcus upon mixture. Enough of the mixture was placed into the sulcus to fill the sulcus while ensuring the mixture stayed 3 mm below the top of the gingival margin and remained immersed in blood.
  • the patient's mouth was kept open for 5 minutes to ensure the newly formed blood clot containing the substrate mixture remained intact.
  • a patient's pocket depths at tooth 28 were measured at 17 separate loci.
  • the treatment disclosed herein was performed on five subsequent occasions, at which time the pocket depths at each loci were measured prior to treatment. Measurements are shown in Fig. 12. The data show an increase in calcium density across all loci.
  • a patient's pocket depths at tooth 2, tooth 3 and tooth 1 S were measured at three separate loci per tooth.
  • the treatment disclosed herein was performed 3 months after the initial treatment, at which time the pocket depths at each loci were measured prior to treatment. Measurements are shown in Fig. 13.
  • the data show a progression of bone generation.
  • ⁇ patient's chin profile was measured.
  • the treatment disclosed herein was performed once after the initial measurements were taken with measurements repeated following treatment. Measurements are shown in Fig. 24.
  • the data show a general increase in chin profile following a single treatment.
  • a patient's toe crease length was measured.
  • the treatment disclosed herein was performed after initial measurements were obtained with measurements repeated following treatment. Measurements are shown in Fig. 25.
  • the data show a 71% overall decrease in crease size following treatment
  • a patient's gingival wounds were measured from the line to the top of the gingiva.
  • the treatment disclosed herein was performed and measurements were repeated following treatment. Images of gingival wounds are shown before and after treatment in Fig. 26a and 26b.
  • a patient's skin leg wound was measured.
  • the treatment disclosed herein was performed after initial measurements were taken with measurements repeated following treatment.
  • Fig. 28 The data show an overall increase in new skin growth following treatment.
  • chronic wounds on limbs may be treated using a three-sided LED system wherein the treatment unit is placed around the limb on three sides and applies the LED energy to a larger surface area.
  • the LED system uses an energy source no greater than 60 mW.
  • a patient's anal scar tissue was measured.
  • the treatment disclosed herein was performed after initial measurements were taken with measurements repeated following treatment.
  • Tongue strength and swallowing was assessed for three patients.
  • the treatment disclosed herein was performed after initial assessments were made and tongue strength and swallowing were reevaluated following treatment. Measurements are shown in Fig. 31. The data show each patient experiencing an increase in tongue strength following treatment
  • the epithelial wound regeneration of a patient was assessed.
  • the treatment disclosed herein was performed after initial wound measurement and wound size was remeasured following treatment. Comparative measurements are shown in Fig. 38.
  • Epithelial regeneration was found to have increased in area by 170% one day following treatment.
  • the calcaneal tendon wound regeneration of a patient was assessed.
  • the treatment disclosed herein was performed after initial wound measurement and wound size was remeasured following treatment. Comparative measurements are shown in Fig. 39. Tendon shelf size increased four times from the initial measurement to the third and final measurement.
  • the ankle epithelial wound regeneration of a patient was assessed.
  • the treatment disclosed herein was performed after initial wound measurement and wound size was remeasured following treatment. Comparative measurements for two treatment areas are shown in Fig. 40. Epithelial regeneration was found to have increased in area by 264% five months following treatment.
  • the ankle epithelial wound size reduction of a patient was assessed.
  • the treatment disclosed herein was performed after initial wound measurement and wound size was remeasured following treatment. Comparative measurements for two treatment areas are shown in Fig. 41. Epithelial wound size was found to have decreased in area by 72% five months following treatment. XV. Analysis of Oral Cavity Wound Regeneration
  • the oral cavity epithelial wound regeneration of a patient was assessed.
  • the treatment disclosed herein was performed after initial wound measurement and wound size was remcasured following treatment. Comparative measurements are shown in Fig. 42.
  • Epithelial regeneration size increased by 1.34 cm 2 from the initial measurement to the fourth and final measurement.
  • the vein wound regeneration of a patient was assessed.
  • the treatment disclosed herein was performed after initial wound measurement and wound size was remeasured following treatment. Comparative measurements are shown in Fig. 43a. Epithelial regeneration size increased by 2.9 cm 2 from the initial measurement to final measurement.
  • Treatment was conducted using a flashlight style infrared laser as shown in Fig. 43b wherein the LED beam is a concentrated flat line of light applied to the skin and veins.
  • the flashlight style laser is a self- contained modular laser that allows for manipulation of skin around a wound during treatment. Alternatively, a LED panel may be used.
  • One embodiment of the present invention provides a device for treating a wound according to the method described herein, the device emitting a laser a beam of light having a wavelength in the green wavelength range (520-570 nm), red wavelength range (620-750 nm), or yellow wavelength range (570-590 nm) having an alternative wattage of 0.001 W to 5W, preferably 0.002W to 4W, more preferably 0.003 W to 3 W, and most preferably 0.005W to 2 W.
  • the laser light utilizes the IR wavelength range (700nm - 1400nm) at a laser power of .001 W to 5W to treat wounds.
  • a LED light utilizes the IR wavelength range to treat wounds.
  • a device for treating a wound according to the method described herein the device emitting a RF beam up to 10W comprised of a carrier wave frequency in the range of 0.1 MHz to 20MHz and a non-sinusoidal waveform in the range of 0 to 40 KHz.
  • the carrier wave frequency is in the range of 0.2MHz to 10MHz, preferably 0.3MHz to 5MHz.
  • a 0.001 W to 10W range RF energy preferably a 0.001W to 3W range, is utilized in the hertz range of 40 Hz to 24 GHz.
  • the RF wave is more than one sine wave wherein the more than one demonstrates a harmonics pattern.
  • the non-sinusoidal waveform may be in the range of the above parameters in the absence of a carrier wave.
  • Yet another embodiment of the present invention provides a device for treatment of a wound according to the method described herein, the device emitting a laser beam, a RF beam or a combination thereof.
  • Still another embodiment of the present invention provides a device for treatment of wounds in the oral cavity according to the method described herein, the device emitting a fiber optic laser beam.
  • the fiber optic device may be used in conjunction with the laser and RF device for treating general wounds and wounds of the oral cavity.
  • the device emits a LED light.

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

Procédé de traitement de tissu malade tout en cicatrisant la plaie à l'aide d'une diode laser qui produit un faisceau de lumière ayant une longueur d'onde dans la partie visible du spectre électromagnétique (400 nm-700 nm) à une puissance laser de 0 001 à 1,2 watts, utilisée avec des arrêts intermittents pour réguler la température du tissu et la régénération épithéliale de biostimulation lorsqu'utilisée avec ou sans substrat. L'invention porte aussi sur un procédé de traitement de tissu malade à l'aide d'une lumière laser dans la plage de longueur d'onde verte (520-570 nm) à une puissance laser de 0,001 W à 5 W. L'invention porte également sur un procédé de traitement de tissu malade à l'aide d'une lumière laser dans la plage de longueur d'onde IR (700-1400 nm) à une puissance laser de 0,001 W à 5 W.
PCT/US2016/061423 2015-11-10 2016-11-10 Système et protocole de cicatrisation de plaie assistée par laser Ceased WO2017083579A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA3005045A CA3005045C (fr) 2015-11-10 2016-11-10 Systeme et protocole de cicatrisation de plaie assistee par laser
CN201680072908.0A CN108430577A (zh) 2015-11-10 2016-11-10 激光辅助的创伤愈合方案和系统
JP2018525412A JP2019502425A (ja) 2015-11-10 2016-11-10 レーザ支援の創傷治癒のプロトコールおよびシステム
AU2016353150A AU2016353150B2 (en) 2015-11-10 2016-11-10 Laser assisted wound healing protocol and system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/937,858 2015-11-10
US14/937,858 US11730760B2 (en) 2011-04-01 2015-11-10 Laser assisted wound healing protocol and system
US15/348,793 US11389663B2 (en) 2011-04-01 2016-11-10 Laser assisted wound healing protocol and system
US15/348,793 2016-11-10

Publications (1)

Publication Number Publication Date
WO2017083579A1 true WO2017083579A1 (fr) 2017-05-18

Family

ID=58695636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/061423 Ceased WO2017083579A1 (fr) 2015-11-10 2016-11-10 Système et protocole de cicatrisation de plaie assistée par laser

Country Status (4)

Country Link
JP (1) JP2019502425A (fr)
AU (1) AU2016353150B2 (fr)
CA (1) CA3005045C (fr)
WO (1) WO2017083579A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
JP2022544597A (ja) * 2019-08-12 2022-10-19 バイオレージェンテック インコーポレイテッド 創傷治癒及び組織再生特性を有する治療システム、デバイス及び組成物、その使用、並びに対応する方法
US11654293B2 (en) 2016-11-10 2023-05-23 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11745026B2 (en) 2011-04-01 2023-09-05 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232303A1 (en) * 2003-04-25 2003-12-18 Michael Black Hygienic treatments of structures in body cavities
US20040199227A1 (en) * 2001-11-29 2004-10-07 Altshuler Gregory B. Biostimulation of the oral cavity
US20080060148A1 (en) * 2005-03-09 2008-03-13 Pinyayev Aleksey M Sensor responsive electric toothbrushes and methods of use
US20140113243A1 (en) * 2012-10-24 2014-04-24 Biolase, Inc. Handpiece Assembly for Laser Treatment Device
US20150164618A1 (en) * 2012-04-13 2015-06-18 OrthoAccel Technologies, Inc Laser orthodontic devices

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730760B2 (en) * 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040199227A1 (en) * 2001-11-29 2004-10-07 Altshuler Gregory B. Biostimulation of the oral cavity
US20030232303A1 (en) * 2003-04-25 2003-12-18 Michael Black Hygienic treatments of structures in body cavities
US20080060148A1 (en) * 2005-03-09 2008-03-13 Pinyayev Aleksey M Sensor responsive electric toothbrushes and methods of use
US20150164618A1 (en) * 2012-04-13 2015-06-18 OrthoAccel Technologies, Inc Laser orthodontic devices
US20140113243A1 (en) * 2012-10-24 2014-04-24 Biolase, Inc. Handpiece Assembly for Laser Treatment Device

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
US11684797B2 (en) 2011-04-01 2023-06-27 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11745026B2 (en) 2011-04-01 2023-09-05 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11654293B2 (en) 2016-11-10 2023-05-23 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
JP2022544597A (ja) * 2019-08-12 2022-10-19 バイオレージェンテック インコーポレイテッド 創傷治癒及び組織再生特性を有する治療システム、デバイス及び組成物、その使用、並びに対応する方法

Also Published As

Publication number Publication date
AU2016353150A1 (en) 2018-06-28
CA3005045A1 (fr) 2017-05-18
AU2016353150B2 (en) 2021-09-23
CA3005045C (fr) 2023-05-23
JP2019502425A (ja) 2019-01-31

Similar Documents

Publication Publication Date Title
US11730760B2 (en) Laser assisted wound healing protocol and system
US20230211173A1 (en) Laser assisted wound healing protocol and system
US11684797B2 (en) Laser assisted wound healing protocol and system
AU2016353150B2 (en) Laser assisted wound healing protocol and system
US9180319B2 (en) Laser assisted periodontium and osseus regeneration protocol
US20200330753A1 (en) Orthodontic treatment
US20190000594A1 (en) Dental kit
JP2011518215A (ja) 石灰化組織の再石灰化
Aldelaimi et al. Laser-assisted frenectomy using 980nm diode laser
US11654293B2 (en) Laser assisted wound healing protocol and system
RU2719924C2 (ru) Устройство для процедур стерилизации, оборудование, содержащее это устройство, и относящийся к нему способ
RU2457006C1 (ru) Способ лечения заболеваний пародонта
Maheshwari et al. Rapid orthodontics-a critical review
WO2021107824A1 (fr) Procédé de thérapie photodynamique pour des affections de la cavité buccale et photo-sensibilisateur ou gel stomatologique
AU2020200444B2 (en) Laser assisted periodontium and osseus regeneration protocol
EP3538001A1 (fr) Système et protocole de cicatrisation de plaie assistée par laser
CN108430577A (zh) 激光辅助的创伤愈合方案和系统
Subramanya Evaluation of healing effect of laser bandage following gingivectomy-A case report
WO2022039613A1 (fr) Électrode capuchon pour effectuer des procédures dans la cavité buccale
Indrasari Management of pericoronitis of newly-erupted permanent tooth using electrosurgery–A case report
RU2330691C1 (ru) Способ введения лекарственного средства в стоматологии
RU2179417C1 (ru) Способ хирургического лечения дефекта альвеолярной кости при пародонтите
Horzov et al. Periodontology
BG4984U1 (bg) Антикариесен състав
Roukoz et al. Pain Relief of Aphthous Ulcers by Lasers: A Literature Review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16865042

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3005045

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2018525412

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016353150

Country of ref document: AU

Date of ref document: 20161110

Kind code of ref document: A

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 17.07.2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16865042

Country of ref document: EP

Kind code of ref document: A1